id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312172-bkygtdeo	Malhotra, Atul	ACE2, Metformin, and COVID-19	2020-07-31		.txt	text/plain	2115	106	39	Metformin is a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression. Interestingly, SARS-CoV-1 was found to decrease ACE2 expression after binding, and low levels of ACE2 have been implicated in various cardiovascular impairments and acute respiratory distress syndrome (ARDS) (Reddy et al., 2019) . Here, we discuss the rationale for metformin as a safe and currently available therapy that is known to increase ACE2 and may offer cardiopulmonary benefit in patients suffering from COVID-19. Beyond the potential cardiovascular benefits, several studies have suggested metformin may provide pulmonary protection following SARS-CoV-2 infection. If our hypothesis is supported by these studies, it would provide a strong foundation for rational investigations, including clinical trials, focused on metformin as a safe and immediately available treatment for patients infected with SARS-CoV-2. Effect of preadmission metformin use on clinical outcome of acute respiratory distress syndrome among critically ill patients with diabetes	./cache/cord-312172-bkygtdeo.txt	./txt/cord-312172-bkygtdeo.txt